TY - JOUR
T1 - Phenotype standardisation of angioedema in the head and neck region caused by agents acting on the angiotensin system.
AU - Wadelius, Mia
AU - E Marshall, Sara
AU - Islander, Gunilla
AU - Nordang, Leif
AU - Karawajczyk, Malgorzata
AU - Yue, Qun-Ying
AU - Terreehorst, Ingrid
AU - Baranova, Ekaterina V
AU - Hugosson, Svante
AU - Sköldefors, Karin
AU - Pirmohamed, Munir
AU - van der Zee, Anke-Hilse Maitland
AU - Alfirevic, Ana
AU - Hallberg, Pär
AU - N A Palmer, Colin
PY - 2014
Y1 - 2014
N2 - Angioedema is a potentially life-threatening adverse reaction to angiotensin converting enzyme inhibitors and angiotensin receptor blockers. To study the genetic etiology of this rare adverse event, international consortia and multicentre recruitment of patients are needed. To reduce patient heterogeneity, we have standardised the phenotype. In brief, it comprises swelling in the head and neck region that first occurs during treatment. It should not coincide with urticaria or have another likely cause such as hereditary angioedema.Clinical Pharmacology & Therapeutics (2014); Accepted article preview online 24 June 2014; doi:10.1038/clpt.2014.138.
AB - Angioedema is a potentially life-threatening adverse reaction to angiotensin converting enzyme inhibitors and angiotensin receptor blockers. To study the genetic etiology of this rare adverse event, international consortia and multicentre recruitment of patients are needed. To reduce patient heterogeneity, we have standardised the phenotype. In brief, it comprises swelling in the head and neck region that first occurs during treatment. It should not coincide with urticaria or have another likely cause such as hereditary angioedema.Clinical Pharmacology & Therapeutics (2014); Accepted article preview online 24 June 2014; doi:10.1038/clpt.2014.138.
U2 - 10.1038/clpt.2014.138
DO - 10.1038/clpt.2014.138
M3 - Review article
SN - 1532-6535
VL - 96
SP - 477
EP - 481
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 4
ER -